Satellos Bioscience Inc. (MSCL) - Total Liabilities
Based on the latest financial reports, Satellos Bioscience Inc. (MSCL) has total liabilities worth CA$3.50 Million CAD (≈ $2.53 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Satellos Bioscience Inc. (MSCL) cash conversion ratio to assess how effectively this company generates cash.
Satellos Bioscience Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how Satellos Bioscience Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Satellos Bioscience Inc. to evaluate the company's liquid asset resilience ratio.
Satellos Bioscience Inc. Competitors by Total Liabilities
The table below lists competitors of Satellos Bioscience Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Donga Geologic
KO:028100
|
Korea | ₩214.80 Billion |
|
Ilyang Pharm
KO:007570
|
Korea | ₩205.41 Billion |
|
Horizon Gold Ltd
AU:HRN
|
Australia | AU$13.24 Million |
|
IRM ENERGY LTD
NSE:IRMENERGY
|
India | Rs2.70 Billion |
|
Bisalloy Steel Group Ltd
AU:BIS
|
Australia | AU$47.88 Million |
|
Bank Jabar
JK:BJBR
|
Indonesia | Rp195.94 Trillion |
|
MAX Automation SE
XETRA:MXHN
|
Germany | €155.73 Million |
|
Fountaine Pajo
PA:ALFPC
|
France | €185.90 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Satellos Bioscience Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Satellos Bioscience Inc. market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 5.51 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Satellos Bioscience Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Satellos Bioscience Inc. (2019–2024)
The table below shows the annual total liabilities of Satellos Bioscience Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$5.16 Million ≈ $3.73 Million |
+42.25% |
| 2023-12-31 | CA$3.62 Million ≈ $2.62 Million |
+28.06% |
| 2022-12-31 | CA$2.83 Million ≈ $2.05 Million |
+34.51% |
| 2021-12-31 | CA$2.10 Million ≈ $1.52 Million |
+60.21% |
| 2020-12-31 | CA$1.31 Million ≈ $950.00K |
+97.54% |
| 2019-12-31 | CA$664.81K ≈ $480.91K |
-- |
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy di… Read more